Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study published in Nature Communications identifies a key driver of joint and intestinal inflammation that could lead to future treatment of the chronic inflammatory disease.

None © Shutterstock
Joints and tissues are affected by spondyloarthritis (SpA)

Similarly to rheumatoid arthritis, spondyloarthritis (SpA) is a type of chronic inflammatory disease that predominately affects the joints: Ankylosing spondylitis and psoriatic arthritis being the most common forms. SpA affects not only the joints, but also leads to damage to other tissues like the skin and intestine.

Researchers in the Griseri group, using an in vivo model of SpA, revealed that the inflammatory cytokine GM-CSF (granulocyte-macrophage colony stimulating factor) was a key driver of joint and intestinal inflammation. Published in Nature Communications, the study found that one of the ways that GM-CSF exerts its pathogenic effect is by boosting the production of inflammatory white blood cells in the bone marrow, especially neutrophils – a type of white blood cell that protects the body from infections but can also be tissue-toxic when it accumulates in excess. GM-CSF was able to do so not only by promoting the activity of neutrophil progenitor cells, but also that of the upstream "mother cells" of the blood: the haematopoietic stem cells.

The study also revealed a new pathogenic mechanism in SpA as highly proliferative neutrophil progenitor cells accumulated in the bone marrow and also, more surprisingly, directly inside the inflamed joints.

The study highlights GM-CSF as an interesting therapeutic target in SpA, especially as GM-CSF producing cells have been shown to be increased in patients suffering from spondyloarthritis, and as the antibody mediated blockade of GM-CSF activity in rheumatoid arthritis has been shown to be safe and effective in clinical trials.

The work was supported by funding from Versus Arthritis.

Similar stories

Researchers identify link in the treatment of inflammatory bowel disease (IBD)

Kennedy

A new study published in the Journal of Experimental Medicine reveals how IL-10 and PGE2 work together to prevent inflammatory tissue damage and maintain a healthy gut balance

Dissecting TNF signalling in inflammatory disease

Kennedy

New research from Dr Richard Williams’ group at the Kennedy Institute suggests a route for the development of more selective – and effective – therapies for immune-mediated inflammatory disease.

Naturally occurring compound spermidine boosts vaccine responses in old mice

Kennedy

A new study by Kennedy Institute's Professor Katja Simon, and colleagues published in Molecular Cell shows that spermidine, a naturally occurring metabolite found in most human cell types, boosts antibody production in both old mice and immune cells from the elderly.

Dialling down inflammation in psoriasis

Kennedy

A collaborative study between the Kennedy Institute and MRC Weatherall Institute of Molecular Medicine (MRC WIMM) identifies a new pathway that limits the severity of inflammatory skin disease.

Geometry is key to T-cell triggering

Kennedy

Kennedy researchers and Columbia University engineers discover geometric underpinnings of T-cell stimulation through precise engineering of T-cell receptor geometry, building a 3D nanofabricated biomimetic surface that simulates the key components of an antigen-presenting cell.